Pharmagen would recommend to our hospital partners to keep an eye on inventory levels of Ketorolac. Given the the U.S. Food and Drug Administration banned imports from one of the plants of Indian drug maker Wockhardt, we believe there may be a pending shortage of Ketorolac for the foreseeable future. Analysts believe that this shortage may continue for up to two years.....
In May, the FDA imposed ban on the Waluj plant of Wockhardt after inspectors found torn data records in a waste heap and urinals that emptied into an open drain in a bathroom six meters from the entrance to a sterile manufacturing area.
No comments:
Post a Comment